October 23, 2018
FDA: Class I recall of Endologix AFX Endovascular AAA System
Editor's Note
The Food & Drug Administration on October 15 classified the recall by Endologix, Inc, of its AFX Endovascular AAA System as Class I, the most serious.
The recall was initiated because of the risk of Type III endoleaks. When a Type III endoleak occurs, blood continues to flow into the aneurysm, increasing the likelihood of serious injury, rupture, or death.
Free Daily News
- Study: Excessive nurse overtime, agency staffing harm patients
- Commentary: Technology no substitute for cadaver-based medical education
- Study: Early-stage breast cancer surgery may not be necessary after chemo, radiation
- Experimental brain implant translates thoughts to speech
- Nurses deem flexible, transparent scheduling key to satisfaction, retention
- OR Manager 2025 Career/Salary Survey offers opportunities to learn, give back
- The Joint Commission revises volume criteria for cardiac, stroke certifications
- Pulse oximetry monitoring at home found to save lives of high-risk opioid surgery patients
- New data suggest same-day discharge is safe for joint replacement patients with atrial fibrillation
- FBI investigates as Oracle health data breach exposes patient information
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement